Chemotherapy Induced Peripheral Neuropathy Market Size, Share, and Growth Forecast, 2026 – 2033

The global chemotherapy induced peripheral neuropathy market size is likely to be valued at US$1.2 billion in 2026 and is expected to reach US$2.2 billion by 2033, growing at a CAGR of 8.6% during the forecast period from 2026 to 2033, driven by the rising incidence of cancer, which is expanding the population of patients receiving neurotoxic chemotherapy.

Increasing survivorship rates are further contributing to sustained demand for effective neuropathy management solutions. Additionally, evolving treatment approaches are placing greater emphasis on symptom control, thereby boosting the need for supportive therapies. Advancements in sodium channel blockers are anticipated to reshape the standard of care, while the growing demand for non-opioid pain management options continues to support market expansion.